Table 1 Demographic and Clincial Data

Number of patients

10

13

Mean age in years (range)

71 (68–79)

68 (62–84)

0.27

Female (%)

9/10 (90 %)

10/13 (77 %)

0.45

 Alendronate

7 (70 %)

10 (77 %)

0.68

 Ibandronate

2 (20 %)

3 (23 %)

 Risendronate

1 (10 %)

0

Proportion of patients with Vitamin D supplementation (%)

6/10 (60 %)

6/13 (46 %)

0.68

Mean years of bisphosphonate use (range)

9.2 (5–13)

8.8 (5–20)

0.79

Mean years since bisphosphonates stopped

3.6 (1–5)

2.0 (1–4)^a

0.65

Mean alkaline phosphatase in U/L (range)^c

58 (37–73)

56 (38–74)

0.81

Proportion of patients with abnormal alkaline phosphatase (below 50 U/L)

5/10 (40 %)

5/13 (38 %)

Mean pyridoxal 5’ phosphate (PLP) in mcg/L^d

29.8 (5–44)

20.6 (5–118)

0.37

Mean neck-shaft angle degrees (S.D.)

132 (3.1)

136 (5.2)

0.048

Mechanical axis angle degrees^b (S.D.)

−0.71 (5.0)

−0.15 (2.7)

0.76

Lateral distal femoral angle degrees (S.D.)

90.7 (5.0)

90.2 (2.7)

0.76